Reintroducing Yosprala® (aspirin and omeprazole), the ASA therapy for secondary prevention of cardiovascular events for patients at risk of developing aspirin associated gastric ulcers.1


Coordinated, sequential drug delivery via a proprietary system.
Yosprala has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin.1  ASA, Acetylsalicylic acid, CV, cardiovascular, GI, gastrointestinal.

Innovida Savings Program

Your patient may pay as little as $0 for Yosprala

Yosprala Card


Yosprala is designed to sequentially deliver immediate-release omeprazole and delayed-release aspirin1,2

Yosprala is not interchangeable with the individual components of aspirin and omeprazole1

For illustration purposes only. Not a visual representation of the tablet.



Adverse reactions occurring in ≥2% of YOSPRALA-treated patients and more common than in the control arm: gastritis (18% vs 16%), nausea (3% vs 2%), diarrhea (3% vs 2%), gastric polyps (2% vs 1%), noncardiac chest pain (2% vs 1%)1  AE, adverse event, EC, enteric-coated.

*Study design: Efficacy of the omeprazole component in Yosprala was evaluated in 2 randomized, multicenter, double-blind, 6-month, Phase 3 trials in patients who had a cerebrovascular or CV diagnosis and were taking 325 mg of aspirin for ≥3 months, expected to continue treatment for ≥6 months, and at risk for aspirin-associated gastric ulcers based on being ≥55 years-of-age or 18 to 54 years old with a documented history of gastric or duodenal ulcer within the 5 years before study enrollment. Patients received Yosprala 325-mg delayed-release aspirin/40-mg immediate-release omeprazole or 325-mg of enteric-coated aspirin. Gastric and duodenal ulcer formation was assessed by gastroduodenal endoscopy at screening and after 1, 3, and 6 months of treatment.1,3-5


Prescription-strength omeprazole with 2 aspirin strengths1
Administered at least 1 hour before a meal1,*

81-mg delayed-release aspirin/ 40-mg immediate-release omeprazole

325-mg delayed-release aspirin/ 40-mg immediate-release omeprazole

*The tablets are to be swallowed whole with liquid. Do not split, chew, crush, or dissolve the tablet.1
For illustration purposes only. Not a visual representation of the tablets. 


Mechanism of Action

Click the play button to watch the full video

Helpful Documents

General Information

Information for HCP

Information for Patients

References: 1. Yosprala Prescribing Information. Charleston, WV: Innovida Pharmaceutique Corporation 2018. 2. Miner PB, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg–a randomised, phase 1, crossover study. Aliment Pharmacol Ther. 2013;38(1):62-71. 3. Whellan DJ, Goldstein JL, Cryer BL, et al. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. Am Heart J. 2014;168(4):495-502. 4. Data on file. #0266. Innovida Pharmaceutique Corporation 5. Data on file. #0267. Innovida Pharmaceutique Corporation

Yosprala® is a registered trademark of Genus Lifesciences, Inc. and is used under license. All other product/brand names are trademarks of their respective owners.
Manufactured for: Innovida Pharmaceutique Corporation © 2019 Innovida Pharmaceutique Corporation, Inc. All rights reserved. INY-01-001, Rev 05/2020